BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23115024)

  • 21. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2.
    Chang CM; Chang PY; Tu MG; Lu CC; Kuo SC; Amagaya S; Lee CY; Jao HY; Chen MY; Yang JS
    Oncol Rep; 2012 Nov; 28(5):1799-807. PubMed ID: 22923287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caveolin-1 acts as a tumor suppressor by down-regulating epidermal growth factor receptor-mitogen-activated protein kinase signaling pathway in pancreatic carcinoma cell lines.
    Han F; Gu D; Chen Q; Zhu H
    Pancreas; 2009 Oct; 38(7):766-74. PubMed ID: 19893453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
    Staverosky JA; Muldoon LL; Guo S; Evans AJ; Neuwelt EA; Clinton GM
    Clin Cancer Res; 2005 Jan; 11(1):335-40. PubMed ID: 15671564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapamycin inhibits the growth of glioblastoma.
    Arcella A; Biagioni F; Antonietta Oliva M; Bucci D; Frati A; Esposito V; Cantore G; Giangaspero F; Fornai F
    Brain Res; 2013 Feb; 1495():37-51. PubMed ID: 23261661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
    Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
    de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
    Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
    Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
    PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of an EGFRvIII-JNK2-HGF/c-Met-Signaling Axis Required for Intercellular Crosstalk and Glioblastoma Multiforme Cell Invasion.
    Saunders VC; Lafitte M; Adrados I; Quereda V; Feurstein D; Ling Y; Fallahi M; Rosenberg LH; Duckett DR
    Mol Pharmacol; 2015 Dec; 88(6):962-9. PubMed ID: 26452771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ciclopirox and bortezomib synergistically inhibits glioblastoma multiforme growth via simultaneously enhancing JNK/p38 MAPK and NF-κB signaling.
    Su Z; Han S; Jin Q; Zhou N; Lu J; Shangguan F; Yu S; Liu Y; Wang L; Lu J; Li Q; Cai L; Wang C; Tian X; Chen L; Zheng W; Lu B
    Cell Death Dis; 2021 Mar; 12(3):251. PubMed ID: 33674562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The p38-MK2-HuR pathway potentiates EGFRvIII-IL-1β-driven IL-6 secretion in glioblastoma cells.
    Gurgis FM; Yeung YT; Tang MX; Heng B; Buckland M; Ammit AJ; Haapasalo J; Haapasalo H; Guillemin GJ; Grewal T; Munoz L
    Oncogene; 2015 May; 34(22):2934-42. PubMed ID: 25088200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.
    El Meskini R; Iacovelli AJ; Kulaga A; Gumprecht M; Martin PL; Baran M; Householder DB; Van Dyke T; Weaver Ohler Z
    Dis Model Mech; 2015 Jan; 8(1):45-56. PubMed ID: 25431423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines.
    Halatsch ME; Gehrke EE; Vougioukas VI; Bötefür IC; A-Borhani F; Efferth T; Gebhart E; Domhof S; Schmidt U; Buchfelder M
    J Neurosurg; 2004 Mar; 100(3):523-33. PubMed ID: 15035290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization.
    Hayashi K; Michiue H; Yamada H; Takata K; Nakayama H; Wei FY; Fujimura A; Tazawa H; Asai A; Ogo N; Miyachi H; Nishiki T; Tomizawa K; Takei K; Matsui H
    Sci Rep; 2016 Mar; 6():23372. PubMed ID: 26988603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
    Kiguchi K; Kitamura T; Moore T; Rumi M; Chang HC; Treece D; Ruffino L; Connolly K; DiGiovanni J
    Cancer Prev Res (Phila); 2010 Aug; 3(8):940-52. PubMed ID: 20682802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma.
    Zheng Q; Han L; Dong Y; Tian J; Huang W; Liu Z; Jia X; Jiang T; Zhang J; Li X; Kang C; Ren H
    Neuro Oncol; 2014 Sep; 16(9):1229-43. PubMed ID: 24861878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Guanylate binding protein-1 mediates EGFRvIII and promotes glioblastoma growth in vivo but not in vitro.
    Lan Q; Wang A; Cheng Y; Mukasa A; Ma J; Hong L; Yu S; Sun L; Huang Q; Purow B; Li M
    Oncotarget; 2016 Mar; 7(9):9680-91. PubMed ID: 26848767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MUC4 modulates human glioblastoma cell proliferation and invasion by upregulating EGFR expression.
    Li W; Wu C; Yao Y; Dong B; Wei Z; Lv X; Zhang J; Xu Y
    Neurosci Lett; 2014 Apr; 566():82-7. PubMed ID: 24582898
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LRIG3 modulates proliferation, apoptosis and invasion of glioblastoma cells as a potent tumor suppressor.
    Guo D; Yang H; Guo Y; Xiao Q; Mao F; Tan Y; Wan X; Wang B; Lei T
    J Neurol Sci; 2015 Mar; 350(1-2):61-8. PubMed ID: 25708990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXC2 often overexpressed in glioblastoma enhances proliferation and invasion in glioblastoma cells.
    Li W; Fu X; Liu R; Wu C; Bai J; Xu Y; Zhao Y; Xu Y
    Oncol Res; 2013; 21(2):111-20. PubMed ID: 24406047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.